A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Latest Information Update: 23 Jul 2024
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Talquetamab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MonumenTAL-2
- Sponsors Janssen Research & Development
- 17 Jul 2024 Planned End Date changed from 1 Oct 2025 to 29 Sep 2025.
- 14 Jun 2024 According to a Janssen media release, the updated data from this trial were featured as a poster presentation at the 2024 EHA Congress.
- 14 Jun 2024 Results presented in the Janssen media release.